Harvard Scientist Wins £50k Lush Prize for Cervix‑Vagina Organ‑on‑Chip
Dr Zohreh Izadifar receives the £50,000 Lush Prize for creating the first human cervix‑vagina organ‑on‑chip, a tool that mimics hormonal, microbial and infection responses to advance women’s health research.
World’s first human cervix chips among Lush Prize 2026 winners
TL;DR: Dr Zohreh Izadifar of Harvard will accept the £50,000 Lush Prize for Science on 12 May for creating the first human cervix‑vagina organ‑on‑chip that replicates hormonal, microbial and infection responses. The award highlights a field where only 2 % of public research funds target pregnancy and reproductive health.
Context
Women’s health research receives a small slice of public investment, with just two percent of funds directed toward pregnancy, childbirth and reproductive conditions.
This imbalance persists despite women comprising half the global population.
Historically, studies have relied on animal models that do not menstruate, undergo menopause or mirror the human vaginal microbiome, limiting the relevance of findings.
Organ‑on‑chip technology offers a human‑based alternative that can reduce reliance on animal testing.
Key Facts
The Lush Prize ceremony in London will honor Dr Izadifar for her role in developing a palm‑sized chip that integrates living cervical and vaginal epithelial cells with micro‑sensors.
She stated that the platform "produced the first human cervix and vagina chip models that accurately mimic tissue responses to hormones, beneficial bacteria, and infections."
Validation involved exposing the chips to estrogen, progesterone, Lactobacillus spp. and pathogens such as Gardnerella vaginalis, measuring real‑time electrical readouts.
The work is an in‑vitro proof‑of‑concept study; the exact number of donor tissue samples used has not been disclosed in public announcements.
Only 2 % of public research funding supports pregnancy and reproductive health, underscoring the gap the project aims to fill.
What It Means
These organ‑on‑chip models enable scientists to observe how cervical and vaginal tissues react to hormonal cycles, probiotic treatments and infectious agents without using animals.
The sensor readouts provide quantitative data that can accelerate drug screening and improve understanding of conditions like bacterial vaginosis, infertility and pre‑term birth.
By offering a reproducible, human‑relevant system, the technology could lower research costs and increase the translatability of preclinical findings.
Researchers note that further steps include scaling the chip for high‑throughput use, conducting comparative studies with clinical data, and pursuing regulatory qualification for safety testing.
What to watch next: peer‑reviewed publications detailing the chip’s performance, potential collaborations with pharmaceutical companies for toxicity screening, and updates on any follow‑on grants that target the remaining 98 % of reproductive‑health research funding.
Continue reading
More in this thread
Conversation
Reader notes
Loading comments...